Evidence map›Paper›PMID 18948588›Full record

ReviewBlood2008

The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases.

Irving L Weissman, Judith A Shizuru

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07213726 (Quantification of Peripheral Hematopoietic Progenitor Cell Circulation Following Repeated Acute, Vascular Restriction Resistance Exercise Using the Delfi Tourniquet System), which is not on this map. Cited by 213 papers.

0numbers the graph read from it
0cells of the map it votes in
213citing papers in PubMed
17.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07213726 naactive not recruitingnot on this mapstarted 2022, after this paper: background citation

Quantification of Peripheral Hematopoietic Progenitor Cell Circulation Following Repeated Acute, Vascular Restriction Resistance Exercise Using the Delfi Tourniquet System

TypeinterventionalSponsorAndrews Research & Education FoundationRan2022 to 2026Enrolled15ConditionsBlood Flow Restriction (BFR) Training EffectsArmsDelfi Personalized Tourniquet System
3 · Its place in the literature

Who cites it

213 citing papers in PubMed, 469 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

153 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Irving L WeissmanStanford Institute of Stem Cell Biology and Regenerative Medicine, Stanford, CA 94304-1334, USA. irv@stanford.edu
Judith A Shizuru
Institute for Stem Cell Biology and Regenerative Medicine · INStanford University · US

Funding

TLI/ATG CONDTIONING: KIDNEY/BLOOD STEM CELL TRANSPLANTSP01HL075462 · NHLBI · STANFORD UNIVERSITY · PI ENGLEMAN, EDGAR G. · 2004 to 2020
$27.9M
HSC Diversity: Regulation by Clonal Selection vs Epigenetic InductionR01CA086065 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2000 to 2017
$6.9M
MOLECULAR CHARACTERIZATION OF ACUTE MYELOID LEUKEMIAR01CA086017 · NCI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 2000 to 2015
$5.5M
HOMING RECEPTOR DETERMINANTS ON HSCR01HL058770 · NHLBI · STANFORD UNIVERSITY · PI WEISSMAN, IRVING L. · 1998 to 2013
$3.9M
Hematopoietic cell Transplants for Autoimmune DiseasesR01AI049331 · NIAID · STANFORD UNIVERSITY · PI SHIZURU, JUDITH ANNE · 2001 to 2005
$1.6M
Barriers to Allogeneic Hematopoietic Stem Cell EngraftmentR01HL087240 · NHLBI · STANFORD UNIVERSITY · PI SHIZURU, JUDITH ANNE · 2007 to 2010
$1.5M
Diabetes Allele Transfer by Hematopoietic Cell Transpl.R01DK067559 · NIDDK · STANFORD UNIVERSITY · PI SHIZURU, JUDITH ANNE · 2004 to 2006
$735k
NCI NIH HHS CA086065NCI NIH HHS CA86017NCI NIH HHS R01 CA086017NCI NIH HHS R01 CA086065NHLBI NIH HHS HL058770NHLBI NIH HHS HL075462NHLBI NIH HHS HL087240NHLBI NIH HHS P01 HL075462NHLBI NIH HHS R01 HL058770NHLBI NIH HHS R01 HL087240NIAID NIH HHS AI049331NIAID NIH HHS R01 AI049331NIDDK NIH HHS DK067559NIDDK NIH HHS R01 DK067559
6 · The paper itself

Abstract

Advances in the understanding of the cells of the hematopoietic system have provided a rich basis for improving clinical hematopoietic cell transplants; finding and using proteins and molecules to amplify or suppress particular blood cell types; understanding the stepwise progression of preleukemic stages leading first to chronic myeloid disorders, then the emergence of acute blastic leukemias; and treating malignant and nonmalignant diseases with cell subsets. As a result of intense scientific investigation, hematopoietic stem cells (HSCs) have been isolated and their key functional characteristics revealed-self-renewal and multilineage differentiation. These characteristics are now found to be present in all tissue/organ stem cell studies, and even in the analysis of pluripotent embryonic, nuclear transfer, and induced pluripotent stem cells. Studies on HSC have identified hematopoiesis as one of the best systems for studying developmental cell lineages and as the best for understanding molecular changes in cell fate decision-making and for finding preclinical and clinical platforms for tissue and organ replacement, regeneration, and oncogenesis. Here we review the steps, from our viewpoint, that led to HSC isolation and its importance in self-nonself immune recognition.

Indexed as

AnimalsAutoimmune DiseasesCell SeparationHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHumansImmune ToleranceMiceTerminology as TopicTissue DonorsTransplantation, AutologousTransplantation, HomologousTransplantation Immunology

Identifiers

PMID18948588
PMCPMC2574516
OpenAlexW2009758262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.